These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26703796)

  • 1. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P; Bollig-Fischer A
    Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
    Gadgeel SM
    Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of relapsed/refractory NSCLC with chemical drugs.
    Karachaliou N; Sosa AE; Barron FB; Gonzalez Cao M; Santarpia M; Rosell R
    Expert Opin Pharmacother; 2017 Feb; 18(3):295-304. PubMed ID: 28103738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
    Chen XX; Zhou CC
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
    [No Abstract]   [Full Text] [Related]  

  • 11. Acquired resistance in oncogene-addicted non-small-cell lung cancer.
    Sini C; Tuzi A; Rossi G; Russo A; Pezzuto A
    Future Oncol; 2018 Jun; 14(13s):29-40. PubMed ID: 29989451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L; Li Y; Zhang SB; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on systemic therapy of advanced non-small-cell lung cancer.
    Cufer T; Knez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.